Literature DB >> 20229875

Comparison of organ doses for patients undergoing balloon brachytherapy of the breast with HDR 192Ir or electronic sources using monte carlo simulations in a heterogeneous human phantom.

Matthew M Mille1, X George Xu, Mark J Rivard.   

Abstract

PURPOSE: Accelerated partial breast irradiation via interstitial balloon brachytherapy is a fast and effective treatment method for certain early stage breast cancers. The radiation can be delivered using a conventional high-dose rate (HDR) 192Ir gamma-emitting source or a novel electronic brachytherapy (eBx) source which uses lower energy x rays that do not penetrate as far within the patient. A previous study [A. Dickler, M. C. Kirk, N. Seif, K. Griem, K. Dowlatshahi, D. Francescatti, and R. A. Abrams, "A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapy," Brachytherapy 6, 164-168 (2007)] showed that the target dose is similar for HDR 192Ir and eBx. This study compares these sources based on the dose received by healthy organs and tissues away from the treatment site.
METHODS: A virtual patient with left breast cancer was represented by a whole-body, tissue-heterogeneous female voxel phantom. Monte Carlo methods were used to calculate the dose to healthy organs in a virtual patient undergoing balloon brachytherapy of the left breast with HDR 192Ir or eBx sources. The dose-volume histograms for a few organs which received large doses were also calculated. Additional simulations were performed with all tissues in the phantom defined as water to study the effect of tissue inhomogeneities.
RESULTS: For both HDR 192Ir and eBx, the largest mean organ doses were received by the ribs, thymus gland, left lung, heart, and sternum which were close to the brachytherapy source in the left breast, eBx yielded mean healthy organ doses that were more than a factor of approximately 1.4 smaller than for HDR 192Ir for all organs considered, except for the three closest ribs. Excluding these ribs, the average and median dose-reduction factors were approximately 28 and approximately 11, respectively. The volume distribution of doses in nearby soft tissue organs that were outside the PTV were also improved with eBx. However, the maximum dose to the closest rib with the eBx source was 5.4 times greater than that of the HDR 192Ir source. The ratio of tissue-to-water maximum rib dose for the eBx source was approximately 5.
CONCLUSIONS: The results of this study indicate that eBx may offer lower toxicity to most healthy tissues, except nearby bone. TG-43 methods have a tendency to underestimate dose to bone, especially the ribs. Clinical studies evaluating the negative health effects caused by irradiating healthy organs are needed so that physicians can better understand when HDR 192Ir or eBx might best benefit a patient.

Entities:  

Mesh:

Year:  2010        PMID: 20229875      PMCID: PMC2905452          DOI: 10.1118/1.3292292

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  30 in total

1.  Contrast effects on dosimetry of a partial breast irradiation system.

Authors:  Bassel Kassas; Firas Mourtada; John L Horton; Richard G Lane
Journal:  Med Phys       Date:  2004-07       Impact factor: 4.071

2.  A CT-based analytical dose calculation method for HDR 192Ir brachytherapy.

Authors:  Emily Poon; Frank Verhaegen
Journal:  Med Phys       Date:  2009-09       Impact factor: 4.071

3.  Monte Carlo-aided dosimetry of a new high dose-rate brachytherapy source.

Authors:  G M Daskalov; E Löffler; J F Williamson
Journal:  Med Phys       Date:  1998-11       Impact factor: 4.071

4.  First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial.

Authors:  Frank A Vicini; Peter D Beitsch; Coral A Quiet; Angela Keleher; Delia Garcia; Howard C Snider; Mark A Gittleman; Victor J Zannis; H Kuerer; Eric B Whitacre; Pat W Whitworth; Richard E Fine; Bruce G Haffty; L Stacey Arrambide
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

5.  Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine.

Authors:  R Nath; L L Anderson; G Luxton; K A Weaver; J F Williamson; A S Meigooni
Journal:  Med Phys       Date:  1995-02       Impact factor: 4.071

6.  Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.

Authors:  David E Wazer; Seth Kaufman; Laurie Cuttino; Thomas DiPetrillo; Douglas W Arthur
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-24       Impact factor: 7.038

7.  Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries.

Authors:  Sarah C Darby; Paul McGale; Carolyn W Taylor; Richard Peto
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

8.  Effective dose for patients undergoing coronary and femoral intravascular radiotherapy involving an HDR 192Ir source.

Authors:  X George Xu
Journal:  Radiat Prot Dosimetry       Date:  2005       Impact factor: 0.972

9.  Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89.

Authors: 
Journal:  Ann ICRP       Date:  2002

10.  MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis.

Authors:  Neenad M Shah; Todd Tenenholz; Douglas Arthur; Thomas DiPetrillo; Bruce Bornstein; Gene Cardarelli; Zhen Zheng; Mark J Rivard; Seth Kaufman; David E Wazer
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860

View more
  8 in total

Review 1.  Electronic brachytherapy--current status and future directions.

Authors:  D J Eaton
Journal:  Br J Radiol       Date:  2015-03-06       Impact factor: 3.039

Review 2.  Brachytherapy in the treatment of breast cancer.

Authors:  Xinna Deng; Haijiang Wu; Fei Gao; Ye Su; Qingxia Li; Shuzhen Liu; Jianhui Cai
Journal:  Int J Clin Oncol       Date:  2017-06-29       Impact factor: 3.402

Review 3.  An exponential growth of computational phantom research in radiation protection, imaging, and radiotherapy: a review of the fifty-year history.

Authors:  X George Xu
Journal:  Phys Med Biol       Date:  2014-08-21       Impact factor: 3.609

4.  Incorporation of Electronic Brachytherapy for Skin Cancer into a Community Dermatology Practice.

Authors:  Stephen Doggett; Mark Willoughby; Cole Willoughby; Erick Mafong; Amy Han
Journal:  J Clin Aesthet Dermatol       Date:  2015-11

5.  Computed organ doses to an Indian reference adult during brachytherapy treatment of esophagus, breast, and neck cancers.

Authors:  Biju Keshavkumar
Journal:  J Med Phys       Date:  2012-07

6.  Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis.

Authors:  William C Dooley; James C Wurzer; Mohamed Megahy; Gary Schreiber; Tapan Roy; Gary Proulx; Susan Laduzinsky; Steven Lane; James Dalzell; Kambiz Dowlatshahi; Dwelvin Simmons; John P Thropay; Harish Ahuja; Peter Beitsch; Randall W Holt; Charles A Lee
Journal:  Onco Targets Ther       Date:  2011-01-12       Impact factor: 4.147

7.  Post-surgical treatment of early-stage breast cancer with electronic brachytherapy: an intersociety, multicenter brachytherapy trial.

Authors:  Peter D Beitsch; Rakesh R Patel; John D Lorenzetti; James C Wurzer; James C Tucker; Susan J Laduzinsky; Morris A Kugler
Journal:  Onco Targets Ther       Date:  2010-10-29       Impact factor: 4.147

8.  High-Dose-Rate (192)Ir Brachytherapy Dose Verification: A Phantom Study.

Authors:  Alireza Nikoofar; Zohreh Hoseinpour; Seied Rabi Mahdavi; Hadi Hasanzadeh; Mostafa Rezaei Tavirani
Journal:  Iran J Cancer Prev       Date:  2015-05-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.